جلد 6، شماره 4 - ( 8-1401 )                   جلد 6 شماره 4 صفحات 5-1 | برگشت به فهرست نسخه ها

XML Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

McCroskie L, Mahonski S, Walker P D, Dalia S. Successful Treatment of Monoclonal Gammopathy of Renal Significance With Bortezomib in the Setting of Post- Viral SARs-CoV-2 Infection: Case Report. Multidiscip Cancer Investig 2022; 6 (4) :1-5
URL: http://mcijournal.com/article-1-351-fa.html
Successful Treatment of Monoclonal Gammopathy of Renal Significance With Bortezomib in the Setting of Post- Viral SARs-CoV-2 Infection: Case Report. نشریه بین المللی چند تخصصی سرطان 1401; 6 (4) :5-1

URL: http://mcijournal.com/article-1-351-fa.html


چکیده:   (174 مشاهده)
Introduction: Monoclonal Gammopathy of Renal Significance (MGRS) is an immunoglobulin proliferative disorder that leads to the destruction of the renal glomerular basement membrane and progression to end-stage renal disease. The pathogenesis of MGRS is similar to that of multiple myeloma and chronic lymphocytic lymphoma but lacks criteria for either disease. This inability to characterize the disease creates a gap in diagnostic and treatment recommendations. Recent studies and observations suggest that the pathogenesis of MGRS correlates with an acute inflammatory reaction as seen in postviral SARS-CoV-2 (COVID-19) patients.
Case presentation: Here, we present a 61-year-old male with MGRS following a COVID-19 diagnosis with signs of acute kidney injury (AKI). The diagnosis was one of exclusion following kidney and bone marrow biopsy that showed four percent plasma cells and monoclonal protein IgG lambda light chains which did not meet the criteria for multiple myeloma. Historically the treatment of MGRS has targeted the underlying kidney pathology; however, evidence now supports treatment customization to the nature of the clonal M protein proliferation involved in the pathogenesis of the disease.
Conclusion: This case study demonstrates the novel finding of COVID-19-induced MGRS, which was successfully treated with dexamethasone and bortezomib to reduce the progression of kidney injury in MGRS.
متن کامل [PDF 1112 kb]   (170 دریافت)    

دریافت: 1401/2/28 | پذیرش: 1401/6/30 | انتشار الکترونیک: 1401/7/23

ارسال نظر درباره این مقاله : نام کاربری یا پست الکترونیک شما:
CAPTCHA

بازنشر اطلاعات
Creative Commons License این مقاله تحت شرایط Creative Commons Attribution-NonCommercial 4.0 International License قابل بازنشر است.

کلیه حقوق این وب سایت متعلق به نشریه بین المللی چند تخصصی سرطان می باشد.

طراحی و برنامه نویسی : یکتاوب افزار شرق

© 2023 CC BY-NC 4.0 | Multidisciplinary Cancer Investigation

Designed & Developed by : Yektaweb